Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease

Sickle cell disease (SCD) is an inherited chronic multi-organ system disorder that affects approximately 100,000 individuals in the United States, mostly belonging to minority, under-served populations. SCD is associated with substantial morbidity, premature mortality, individual suffering, health care costs and loss of productivity. Hydroxyurea (HU) the only disease modifying therapy for SCD is efficacious in reducing complications such as pain crisis and acute chest syndrome and improving survival. It is however, vastly underutilized and poorly adhered to because of barriers at the health care system, provider, treatment, socioeconomic, and patient levels. The investigator's overarching hypothesis is that barriers to acceptance and adherence to HU are multi-factorial and that a structured set of interventions can lead to improved adherence to medication and patient centered outcomes.

Inclusion criteria

• be >2 years of age up to 65 years of age, inclusive
• have a diagnosis of SCD, with either βS/βS, βS/βC, βS/βD, βS/β0, βS/βO-Arab, or βS/β+ genotype
• prescribed Hydroxyurea for at least the 6 months prior to study entry
• have daily access to a smart phone, tablet, personal computer or other device capable of producing and transmitting videos over the internet
• be willing and able to record and transmit videos

Exclusion criteria

• patient or caregiver refuses to take Hydroxyurea as treatment for SCD
• diagnosis of significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
• an assessment by the investigator that the subject will not comply with the study procedures outlined in the study protocol
• patients receiving automatic home delivery of medications since medication possession ratio is reflective of the patient initiation the refill when they have exhausted the home supply of HU